RxSight (RXST) CEO granted 80,545 RSUs vesting through 2029

Rhea-AI Filing Summary

Kurtz Ronald M MD reported acquisition or exercise transactions in this Form 4 filing.

RxSight, Inc. President & CEO Ronald M. Kurtz received a grant of 80,545 restricted stock units. Each RSU represents a contingent right to receive one share of RxSight common stock.

The award vests in six equal installments, with one-sixth vesting on the first trading day on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029, as long as he continues as a service provider under the company’s 2021 Equity Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kurtz Ronald M MD

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	80,545	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 80,545 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan (the "Plan")) through each applicable date, one-sixth (1/6th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kurtz Ronald M MD

(Last) (First) (Middle)

C/O RXSIGHT, INC.

100 COLUMBIA

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RxSight, Inc. [ RXST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/27/2026		A		80,545		(2)	(2)	Common Stock	80,545	$0	80,545	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan (the "Plan")) through each applicable date, one-sixth (1/6th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jim Schindler, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RxSight (RXST) report for its CEO?

RxSight President & CEO Ronald M. Kurtz received a grant of 80,545 restricted stock units. Each RSU gives a contingent right to one share of common stock, subject to time-based vesting and continued service under the 2021 Equity Incentive Plan.

How many restricted stock units were granted to the RxSight (RXST) CEO?

Ronald M. Kurtz was granted 80,545 restricted stock units. These units were awarded at no stated purchase price per unit and represent potential future shares of RxSight common stock, subject to the vesting schedule and continued service conditions in the company’s equity plan.

What is the vesting schedule for the RxSight (RXST) CEO’s RSU grant?

The RSU grant vests in six equal installments of one-sixth each. Vesting occurs on the first trading day on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029, assuming continued service.

What does each RxSight (RXST) restricted stock unit represent for the CEO grant?

Each restricted stock unit represents a contingent right to receive one share of RxSight common stock. The CEO only receives the underlying shares as the RSUs vest over time and service-based conditions under the 2021 Equity Incentive Plan are satisfied.

Are the RxSight (RXST) CEO’s RSUs subject to continued service conditions?

Yes, vesting of the CEO’s RSU award requires that he continue as a service provider under RxSight’s 2021 Equity Incentive Plan. If service ends before a scheduled vesting date, the unvested portion of the 80,545 RSUs would not be earned under these terms.